CRISPR Statistics By Startups And Facts
Updated · Nov 28, 2024
WHAT WE HAVE ON THIS PAGE
Introduction
CRISPR Statistics: CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technologies have transformed the genetic modification landscape since their invention. Making allows for precise editing of deoxyribonucleic acid and transformative use in health care, farming, and research.
In the year 2024, the globalization of the CRISPR statistics value chain is on the rise owing to the ongoing development of gene-editing ailments and increased R&D activities.
Editor’s Choice
- CRISPR statistics reveal the market is also expected to grow significantly from about 2.4 billion U.S. dollars in 2023 to about 33 billion U.S. dollars in 2033.
- There is great interest in implementing CRISPR-based therapies since clinical trials are showing encouraging results. More than 100 ongoing trials worldwide are on different genetic conditions and diseases.
- Notably, since its inception, CRISPR has attracted a lot of attention in the commercial and research sectors, which is demonstrated by the fact that more than 1000 patents have been registered across the globe.
- Attention to ethical and policy concerns regarding CRISPR has started to increase, with around 50 countries issuing rules and policies addressing ethical concerns.
- There is an upward trend in investments in CRISPR, which have already reached billions thanks in large part to money from public agencies, biotechnologies, and investigative capital.
- CRISPR statistics show that countries such as the US, China and the United Kingdom, which are considered leaders in the development of CRISPR technology, are pursuing its rapid development.
- The precision of CRISPR technology is also improving at a considerable rate, with use efficiency values of 50% to 90% depending on the experiments.
CRISPR Key Facts
- The general public may not be familiar with CRISPR technology, but it is changing the bioscience industry in ways that are hard to imagine.
- In recognition of her valuable contribution to this technology, Jennifer Doudna and Emmanuelle Charptrier won a Nobel Prize in Chemistry in 2020 for having invented this tool, which is expected to change how medicine, agriculture, and a host of other fields operate.
- CRISPR statistics indicate that considering that the size of the global CRISPR genome editing market is estimated to soar to approximately 33 billion U.S. dollars by 2033, it is important to comprehend its importance.
- A household name that stands for Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR serves as accurate editing equipment for genetic materials.
- The realization of this technology was back in the 80s when Japanese molecular biologists noticed gaps in some portions of the DNA of certain bacteria only to find out that they actually formed the building mechanism of a defensive strategy against invading viruses.
- In bacteria, that system consists of “memories” of certain infections contained in small pieces of foreign DNA that are retained over each replication cycle, and the use of those memories to prepare the enzyme Cas9 in the event of re-infection.
- CRISPR statistics state that by 2012, this technology had also been used in gene editing in various other organisms, plants, and animals, including humans.
- The CRISPR-Cas9 system has the capacity to be programmed to bind to specific sites in the target genetic sequence, allowing for the efficient and efficient changes such as deletion, addition, or substitution of the target DNA segment.
- Most of this innovation is from companies and start-ups that are based in the U.S., which captures most of the CRISPR technology space.
- It is no secret that CRISPR has many applications, especially in medicine. Gene therapy provides a beneficial way of remedying genetic disorders as it is capable of rectifying the faulty genes that cause diseases such as cancer and sickle cell anemia.
- For instance, some research found that with the application of CRISPR, the survival rate in cancers presented in mice improved from lower to higher percentages, such as 80 breast cancer survival and 30 ovarian cancer survival rates.
- Furthermore, its use has been extended in the treatment of some diseases, such as those mentioned above, where modification of specific alleles in mosquitos was intended to transfect organisms that spread malaria and help eliminate them.
- CRISPR statistics reveal that during COVID, CRISPR-related tests to check for the presence of the virus were readily available, and before any sample was taken, a treatment to be used against a public health risk in the form of SARS-CoV 2 was already in the works showing the extent to which the technology would be used in solving societal issues. In addition to healthcare, CRISPR technology has enormous prospects in both the agricultural and environmental fields.
- The inventor can manipulate the genes to produce more nutritious crops, have higher yields, and have less allergic properties.
- Nonetheless, the prospects of changing the human genome have raised concerns about their ethical implications, especially with such technologies being applied to human embryos.
- There were ethical concerns surrounding the 2018 announcement by a Chinese scientist that he had created genetically edited embryos to produce children with immunity to thymus-T-cell HIV.
- Increases in genetically modified organism (GMO) food consumption help to understand the extent of acceptance of CRISPR-modified foods despite the new technology being more refined than the older one.
- The development of CRISPR is at a great pace, and the effects may reach out to very many sectors.
- Still, it will be essential to maintain an equilibrium in innovation, ethicality, and regulation to sustain developmental reasoning.
Leading CRISPER Startups
(Reference: statista.com)
- CRISPR statistics state that in July 2024, Intellia Therapeutics became the most well-funded CRISPR-related startup in the world, with total investor contributions reaching approximately 1.5 billion U.S. dollars.
- Such figures indicate the faith that investors have in the company’s creative ideas and what it is capable of in the gene editing space.
- Subsequently, Editas Medicine attracted close to 930 million U.S. dollars in funding, making it the third-best funded CRISPR-focused startup in the global market.
- The two companies remain fiercely competitive in operating in the environment of CRISPR technology, which involves adapting the revolutionary gene editing system for the treatment of hereditary disorders and for other medical uses.
- This statistic speaks to the fierce competition and evolution taking place in the CRISPR sector. It also shows the considerable investment being made towards young companies with transformative ideas for the biotechnology and medical industries.
- Such investments also enable the research and development of CRISPR-based medicines and assist in fast-tracking their clinical and commercial use.
Total Human Genome Funding By The National Institutes For Health
(Reference: statista.com)
- According to CRISPR statistics, for the fiscal year (FY) 2023, the National Institutes of Health (NIH) earmarked around 5 billion U.S. dollars for research associated with the human genome.
- This investment points to the fact that genomics research is still a significant enabling factor in furthering the knowledge of humankind.
- The funding provided by the NIH caters to many aspects of research, such as models of genetic disorders and their treatment, personalized medicine, and state-of-the-art applications of gene editing technologies, including CRISPR.
- This is additionally a specific figure that has been tracked in the long term, as indicated by the data on the costs of studying the human genome by the NIH from FY 2013 through FY 2023.
- Given that these CRISPR statistics also contain forecasted figures for FY 2024 and FY 2025, it can be assumed that the NIH plans to preserve and further enhance its investments in genomic studies.
- Such investments are targeted at forcing the envelope in healthcare, improving disease-suppressing mechanisms, and funding technologies that are meant to change medicine and healthcare in the bioscience industries in a few years.
CRISPER Awarded By FDA
(Source: pharmaceutical-technology.com)
- CRISPR statistics reveal that in the last quarter of 2023, Vertex Pharmaceuticals and CRISPR Therapeutics made a stunning achievement after years of clinical trials and documenting the effectiveness of the CRISPR technology – received the first FDA–approved CRISPR drug ever, exagamglogene autotemcel, also known as Casgevy.
- Most notably, this landmark approval came around the same time when the FDA approved an unprecedented 14 review designations for CRISPR-related therapeutics in the year 2023, indicating a shift in the agency’s focus towards the development of CRISPR drugs.
- On 8th December, the FDA granted marketing authorization to Casgevy for the treatment of Sickle Cell Disease associated with Vaso-Occlusive Crisis, which represents the first multiregional marketing authorization for any CRISPR-Cas9-based therapeutic.
- By way of contrast to old procedures that replace or knock out causing genes, gene editing technologies can fix genes that are present but do not function.
- More specifically, Casgevy, which is a CRISPR-Cas9 product, edits the gene defect in the hematopoietic tissue of the patient stem cells in order to enable hemoglobin synthesis.
- With this novel strategy, patients will not have to undergo bone marrow transplants, which pose high risks, such as rejection of the graft.
- CRISPR statistics state that the FDA’s approval of Casgevy in 2023 also went in hand with a calendar year within which the highest number of CRISPR drug designations occurred, hitting 14 review designations.
- To the best of our knowledge, these included six orphan drug designations, four fast-track designations, two regenerative medicine advanced therapy (RMAT) designations, one pediatric rare disease designation, and one priority review.
- These designations were given to ten different CRISPR therapeutics. Other than that, the trajectory looks promising as this was the first time FDA Norton wore a crisper drug review designation for the first time in the history of development.
- Label 14 for the designated drugs in 2023 is 55% higher than the previous maximum of nine designations granted in both 2021 and 2022. This proves that there is an increasing emphasis on CRISPR-based medicines in solving unmet medical needs, especially serious ones.
CRISPR Valuation Measures
- The following information contains CRISPR statistics information with regard to several financial aspects of the CRISPR over a series of reporting periods, the latest being the current one, the historical quarters ending September 30, 2023, and many others.
- The total worth of shares the company has under creation is referred to as the current market capitalization, which stands at $4.03 billion.
- A year ago, on September 30, 2024, it was $4.01 billion. It was $4.59 billion in the case of June 30, 2024, $5.78 billion during March 31, 2024, and $4.97 billion as of December 31, 2023.
- In these cases, September 30, 2023, showed a market capital of $3.60 billion, indicating trend reversals and advancements. Enterprise value, which includes market cap, debt, and cash, is now $2.32 billion.
- It was $3.74 billion a year back on September 30, 2024, $2.71 billion at the end of the second quarter of 2024, $4.32 billion by the end of the first quarter of 2024, $3.47 billion by the end of the year 2023 and $2.08 billion up to the 30th of September 2023.
- This measure also exhibits variability, signifying the evolution of the company and its investors’ attitudes. The trailing price-to-earnings (P/E) ratio is 22.55, marking the price that investors are willing to pay for a dollar of earnings.
- Operating P/E is somewhat high at 23.36, implying there are expectations for an increase in earnings in the future.
- The price-sales ratio, the common measure that analyses the stock price with revenue per share, is presently 19.59.
- The price-to-book ratio, which reflects the share price relative to the equity’s book value, is currently at 2.08. It was recorded at 2.02 on September 30, 2024, 2.20 on June 30, 2024, 3.07 on March 31, 2024, 2.90 on December 31, 2023, and 1.99 on September 30, 2023.
- The enterprise value to revenue ratio, which determines the company’s worth in relation to its sales, is currently standing at 11.62. The earlier figures include 18.66 as of September 30, 2024, 10.05 as of June 30, 2024, 11.68 as of March 31, 2024, 20.44 for December 31, 2023, and a figure of 12.24 for September 30, 2023.
- The enterprise value to EBITDA multiple is at 14.16 at the moment. While there is no value for most of the previous quarters, a value of 46.64 is taken for December 31, 2023, and a value of -16.33 for September 30, 2023, indicating a change in the profitability and valuation over the period is shown as well.
Conclusion
CRISPR statistics technology, at present, in the year 2024, is one of the most advanced and innovative technologies that is being used in various sectors to improve the quality of life. Thanks to billions of investments and increasing fields of application, the growth of technology will increase tremendously in the next few years. While the research turns up and new treatments are introduced into the market, CRISPR will continue to serve as a crucial part in addressing a few of the critical issues challenging mankind.
FAQ.
CRISPR is a technology that can edit DNA and uses the Cas9 protein to cut to a genomic DNA sequence that is preferred by the user. It has opened new frontiers in genetic manipulation in medicine, agriculture, and research, allowing for almost any kind of modification of the DNA, such as deleting, adding or changing portions of the DNA strand.
2024 marks the continued growth of CRISPR technology as worldwide spending goes into billions of dollars. The U.S., China and the U.K. are among the first countries to provide such development. More than one hundred clinical trials are being conducted for therapies using CRISPR technology to correct gene defects and genetic disorders. The technology has already been patented by more than 1000 patents worldwide, indicating its economic and research value. The market is expected to increase in value from $2.4 billion in 2023 to $33 billion in 2033.
Initial therapy with genetically modified T cells in a patient with relapsed cancer has been shown to be effective. When the CRISPR-based gene editing technology is approved for use in humans, sickle cell disease will be the first disease to be treated with a drug containing this technology. This development marks a significant shift in the treatment and availability of proprietary gene therapies.
While genome editing for therapeutic purposes offers great promise, especially with respect to CRISPR, the implications of such technologies, especially in relation to the human genome, are very disturbing. For example, in 2018, there was a huge uproar when a researcher claimed to have edited embryos in a bid to produce children who could not contract HIV.
The focus of the research has changed in terms of the FDA towards the CRISP-Cas9 therapies. As such, the FDA has approved fourteen (14) Review Designations 2023, Obtaining orphan drug – fast track- regenerative medicine advanced therapy (RMAT ) designations allowing fast tracking of development and approval processes for their customers. The FDA’s approval for the use of Casgevy in treating sickle cell disease is indicative of its strategy for the use of CRISPR technology in drug development for diseases without a cure.
Maitrayee, after completing her graduation in Electrical Engineering, transitioned into the world of writing following a series of technical roles. She specializes in technology and Artificial Intelligence, bringing her experience as an Academic Research Analyst and Freelance Writer, with a focus on education and healthcare under the Australian system. From an early age, writing and painting have been her passions, leading her to pursue a full-time career in writing. In addition to her professional endeavors, Maitrayee also manages a YouTube channel dedicated to cooking.
